Cantourage Group Inkomsten in het verleden
Verleden criteriumcontroles 4/6
Cantourage Group has been growing earnings at an average annual rate of 639.4%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 76.9% per year. Cantourage Group's return on equity is 0.5%, and it has net margins of 10.4%.
Belangrijke informatie
639.4%
Groei van de winst
n/a
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 7.3% |
| Inkomstengroei | 76.9% |
| Rendement op eigen vermogen | 0.5% |
| Nettomarge | 10.4% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Geen updates
Recent updates
Opbrengsten en kosten
Hoe Cantourage Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 2 | 0 | 1 | 0 |
| 31 Mar 24 | 2 | 0 | 1 | 0 |
| 31 Dec 23 | 2 | 0 | 1 | 0 |
| 30 Sep 23 | 1 | 0 | 1 | 0 |
| 30 Jun 23 | 1 | 0 | 0 | 0 |
| 31 Dec 22 | 1 | 0 | 0 | 0 |
| 31 Dec 21 | 5 | -1 | 1 | 0 |
Kwaliteitswinsten: HIGH has high quality earnings.
Groeiende winstmarge: HIGH's current net profit margins (10.4%) are higher than last year (2.5%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: HIGH has become profitable over the past 5 years.
Versnelling van de groei: Insufficient data to compare HIGH's past year earnings growth to its 5-year average.
Winst versus industrie: HIGH earnings growth over the past year (639.4%) exceeded the Pharmaceuticals industry 28.7%.
Rendement op eigen vermogen
Hoge ROE: HIGH's Return on Equity (0.5%) is considered low.